COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN THE TREATMENT OF CHRONIC SYMPTOMATIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN THE NETHERLANDS

被引：0
|
作者：
Kvamme, I [1 ]
de Graaf, G. [1 ]
Nekerman, S. [2 ]
Gijsbers, S. [2 ]
Wester, V [3 ]
Hoogendoorn, M. [1 ]
机构：
[1] Inst Med Technol Assessment, Rotterdam, Netherlands
[2] AstraZeneca, The Hague, Netherlands
[3] Erasmus Univ, Rotterdam, Netherlands
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE583
引用
收藏
页码：S170 / S170
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Liu, Chia-Liang
    Bellows, Brandon K.
    Hernandez, Inmaculada
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Kazi, Dhruv S.
    [J]. JAMA NETWORK OPEN, 2021, 4 (07) : E2114501
  • [2] Cost-effectiveness of Dapagliflozin in Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Bellows, Brandon K.
    Kazi, Dhruv S.
    [J]. CIRCULATION, 2020, 142
  • [3] Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
    Parizo, Justin T.
    Goldhaber-Fiebert, Jeremy D.
    Salomon, Joshua A.
    Khush, Kiran K.
    Spertus, John A.
    Heidenreich, Paul A.
    Sandhu, Alexander T.
    [J]. JAMA CARDIOLOGY, 2021, 6 (08) : 926 - 935
  • [4] Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction
    Nguyen, Bao-Ngoc
    Mital, Shweta
    Bugden, Shawn
    V. Nguyen, Hai
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 376 : 83 - 89
  • [5] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF SYMPTOMATIC CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGAL
    Alarcao, J.
    Ascencao, R.
    Costa, J.
    Gouveia, M.
    Borges, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S104 - S104
  • [6] COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS SACUBITRIL/VALSARTAN FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION
    McEwan, P.
    Darlington, O.
    Bergenheim, K.
    Qin, L.
    [J]. VALUE IN HEALTH, 2020, 23 : S494 - S494
  • [7] Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China
    Yao, Younan
    Zhang, Rongcheng
    An, Tao
    Zhao, Xinke
    Zhang, Jian
    [J]. ESC HEART FAILURE, 2020, 7 (06): : 3582 - 3592
  • [8] COST-EFFECTIVENESS OF USING DAPAGLIFLOZIN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION: A PHARMACOECONOMIC MODEL ANALYSIS
    Cavusoglu, Y.
    Demir, O.
    Dinc, M.
    Ozsoy, A.
    Erdogan, A.
    Ozer, S.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S66 - S66
  • [9] Cost-Effectiveness of Dapagliflozin in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: the DELIVER Trial
    Lin, Lu
    Xiu, Qiu-ping
    Liu, Fei
    Zhang, Hou-jing
    Chen, Yi-feng
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2023,
  • [10] THE COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN TURKEY
    Sarioz, F.
    Ozdemir, O.
    Direk, S.
    Caglar, P.
    Ar, I
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A616 - A616
12345